Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million ( 8% actual, 5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance Q4 2017: EPS -$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance... Read more
QIAGEN to conduct an up to $200 million share repurchase program Venlo, The Netherlands, January 31, 2018 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the... Read more
Thermo Fisher Scientific Uses Tax Reform Benefit to Make Additional Investments in Colleagues, Customers and Communities WALTHAM, Mass., Jan. 31, 2018 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will make additional investments totaling $50 million as a result of the benefit of recently enacted Federal tax reform legislation in... Read more
MORRIS PLAINS, N.J., Jan. 30, 2018 /PRNewswire/ — Honeywell International Inc. (“Honeywell” or the “Company”) (NYSE: HON) today announced the results of its exchange offer for any and all of its outstanding 3.812% Notes due 2047 (the “Original Notes”) issued by the Company for an equal principal amount of its new 3.812% Notes due 2047 (the “Exchange Notes”).... Read more
Agilent and Insight Experience Receive Brandon Hall Group Bronze Award for Excellence Award received for excellence in the Best Unique or Innovative Leadership Development Program category SANTA CLARA, Calif., and CONCORD, Mass., Jan. 30, 2018 Agilent Technologies Inc. (NYSE: A) and Insight Experience, a leading provider of simulation-based leadership development programs, announced today that they... Read more
WASHINGTON, Jan. 30, 2018 /PRNewswire/ — Danaher Corporation (NYSE: DHR) today announced that, effective January 1, 2019, Matthew R. McGrew, Group CFO of the Company’s Diagnostics and Dental platforms, will succeed Daniel L. Comas as Chief Financial Officer. Mr. Comas will continue as an Executive Vice President of the Company, and a member of the Office... Read more
3Q Results, December 31, 2017（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on... Read more
3Q Results, December 31, 2017（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on... Read more
This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that a federal jury in San Francisco has ruled in its favor in a patent infringement suit filed against Ariosa Diagnostics, Inc., now owned by Roche. The jury found that both Ariosa’s previous and current version of the Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430... Read more